Clinical trial
Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer
NCT00087035 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00087035 |
|---|---|
| Title | Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer |
| Official title | Phase II Trial Of TAXOTERE + TARCEVA™ To Treat HRPC In Men ≥ 65 Years Of Age |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | Aventis Pharmaceuticals Industry Genentec |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, erlotinib hydrochloride |
| Enrollment | 1 |
| Start date | May 1, 2004 |
| Primary completion | Jun 1, 2006 |
| Completion | Mar 1, 2008 |
| First posted | Jul 12, 2004 |
| Last update posted | Aug 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: